Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling

Ramkumarie Baliram,1 Li Sun,2 Jay Cao,3 Jinhua Li,2 Rauf Latif,1 Amanda K. Huber,1 Tony Yuen,2 Harry C. Blair,4 Mone Zaidi,2 and Terry F. Davies1

1Thyroid Research Unit and 2The Mount Sinai Bone Program, Department of Medicine, Mount Sinai School of Medicine, and James J. Peters VA Medical Center, New York, New York, USA.
3US Department of Agriculture, Agricultural Research Service, Human Nutrition Research Center, Grand Forks, North Dakota, USA.
4Department of Pathology and of Cell Biology, University of Pittsburgh, and Pittsburgh VA Medical Center, Pittsburgh, Pennsylvania, USA.

The osteoporosis associated with human hyperthyroidism has traditionally been attributed to elevated thyroid hormone levels. There is evidence, however, that thyroid-stimulating hormone (TSH), which is low in most hyperthyroid states, directly affects the skeleton. Importantly, Tshr–/– knockout mice are osteopenic. In order to determine whether low TSH levels contribute to bone loss in hyperthyroidism, we compared the skeletal phenotypes of wild-type and Tshr–/– knockout mice that were rendered hyperthyroid. We found that hyperthyroid mice lacking TSHR had greater bone loss and resorption than hyperthyroid wild-type mice, thereby demonstrating that the absence of TSH signaling contributes to bone loss. Further, we identified a TSH-like factor that may confer osteoprotection. These studies suggest that therapeutic suppression of TSH to very low levels may contribute to bone loss in people.

Introduction

Hyperthyroidism, a common health risk affecting approximately 1 in 100 individuals, is often accompanied by worsening osteoporosis, especially in postmenopausal women (1). There is compelling evidence from early in vitro and more recent mouse genetic studies that both thyroid hormone (T₄) and triiodothyronine (T₃) stimulate the resorption of bone by osteoclasts (2). This leaves no doubt that thyroid hormone excess is a major contributor to the profound bone loss and high risk of fracture in hyperthyroidism. Physiology tells us that high serum thyroid hormone suppresses the production of thyroid-stimulating hormone (TSH) from the anterior pituitary, although in subclinical hyperthyroidism, thyroid hormone levels can be normal, while TSH is low or undetectable. The osteoporosis associated with subclinical hyperthyroidism is therefore unlikely to arise from thyroid hormone excess alone (3).

We and others have shown that, in addition to its known function in stimulating thyroid follicular cells, TSH can act directly on the skeleton (4–8). Activation of the TSH receptor (TSHR) on the osteoclast prevents the resorption of bone (4). When administered intermittently, TSH stimulates osteoblastic bone formation and, in rodent models, rescues ovariectomy-induced bone loss (3–8). In contrast, absence of the TSHR in the global Tshr–/– mouse causes high-turnover osteoporosis (4). That this osteoporosis is not reversed upon thyroid hormone replacement suggests that absent TSH signaling may have a permissive role in causing this bone loss. Epidemiologic evidence favors strong correlations between low TSH and high bone turnover; low TSH and low bone mineral density (BMD); and low TSH and high fracture risk in hyperthyroid patients (9–23). This raises the question of whether low TSH levels might contribute to the bone loss in hyperthyroidism that has been attributed solely to high thyroid hormone levels.

We therefore compared the skeletal phenotypes of wild-type and Tshr–/– mice that were rendered hyperthyroid by the implantation of slow-release 5-mg T₄ pellets. We show that hyperthyroid Tshr–/– mice completely devoid of TSH signaling display higher levels of bone resorption and bone loss compared with hyperthyroid wild-type mice, even though TSH levels in the latter mice become undetectable. This finding not only establishes a role for TSH signaling in thyrotoxic osteoporosis but, equally importantly, suggests that a local TSH-like factor, which we identify as a novel Tshβ splice variant, might offer osteoprotection, even in the context of undetectable serum TSH.

Results and Discussion

To establish a role for attenuated TSHR signaling in hyperthyroid bone loss, we compared hyperthyroid wild-type and Tshr–/– mice for differences in bone mass and bone remodeling. The expectation was that hyperthyroid Tshr–/– mice would show greater bone loss than hyperthyroid wild-type mice, directly implicating low TSH signaling in the pathogenesis of hyperthyroid bone loss. For this, we rendered wild-type and Tshr–/– mice hyperthyroid by adding 0.5% 2-mercapto-1-methyl-imidazole (methylazole) to drinking water for 14 days. Both T₄ and T₃ expectedly declined to low levels, whereas serum TSH rose sharply in both groups (Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI63948DS1). Thereafter, both groups were implanted with either 0-mg or 5-mg sustained-release thyroid hormone (T₄) pellets for 21 days, during which time the mice were fed normal chow. The 0-mg pellet produced no change in serum T₄ levels, while, as expected from the induction of a hypothyroid state, TSH levels rose in wild-type and Tshr–/– mice. In contrast, serum T₄ levels rose and serum TSH declined in mice receiving 5-mg pellets, essentially modeling human hyperthyroidism.

Authorship note: Mone Zaidi and Terry F. Davies contributed equally to this work.
Conflict of interest: Mone Zaidi is a named inventor of a pending patent application filed by Mount Sinai School of Medicine. In the event the pending patent is licensed, he would be entitled to a share of any proceeds. Terry F. Davies is a member of the Board of Kronus Inc. (Star, Idaho, USA).
Citation for this article: J Clin Invest. 2012;122(10):3737–3741. doi:10.1172/JCI63948.
At 21 days, mice in all groups were sacrificed for histomorphometry and bone marker measurements. Figure 1A shows that compared with mice receiving the 0-mg pellet, those receiving a 5-mg pellet displayed a marked reduction in areal bone mineral density (aBMD). This decline was significantly greater in hyperthyroid Tshr–/– mice compared with hyperthyroid wild-type mice. That this difference was seen in the context of similar T4 levels (Supplemental Table 1) established that absent TSH signaling was the cause of the greater bone loss in Tshr–/– mice rendered hyperthyroid. Micro-CT–based volumetric measures, including volumetric BMD (vBMD), bone volume/trabecular volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and connectivity density (Conn.D), all declined significantly in mice receiving the 5-mg pellet versus those implanted with the 0-mg pellet (Figure 1, B and C). Importantly, decrements in vBMD, BV/TV, Tb.Th, and Conn.D were statistically significantly (P < 0.05) greater in Tshr–/– mice compared with wild-type hyperthyroid mice, while differences in Tb.N and trabecular spacing (Tb.Sp) approached significance (0.1 > P > 0.05). This suggests that the major effect of this relatively short treatment is on Tb.Th rather than on Tb.N. No differences were noted in wild-type versus Tshr–/– mice receiving the 0-mg T4 pellet (P > 0.05). Together, the data reaffirm that absence of TSHR in experimentally induced hyperthyroidism can exaggerate the attendant bone loss.

As human hyperthyroidism is associated with high bone turnover (24), dynamic histomorphometry was performed by injecting mice with calcein (15 mg/kg, i.p.) 14 and 4 days prior to sacrifice. Figure 2, A and B, shows increased bone resorption and formation, as evidenced by tartrate-resistant acid phosphatase (TRAP) and calcein labeling, respectively, in Tshr–/– mice rendered hyperthyroid. Individual parameters, namely osteoclast surface (Oc.S/BPm), mineralizing surface (MS), bone formation rate (BFR), and double label fraction (dLS/BPm) increased significantly (P < 0.05) in Tshr–/– mice implanted with 5-mg pellets compared with those receiving 0 mg T4 (Table 1). The increases in Oc.S/BPm and BFR were highly significantly (P = 0.004) and marginally (P = 0.081) greater, respectively, in Tshr–/– hyperthyroid mice compared with wild-type hyperthyroid mice (Table 1), confirming that TSHR deficiency causes the increased bone resorption. The apparent discordance between bone formation and bone resorption was expected, as formation lags behind resorption, which is the primary stimulus causing hyperthyroid bone loss.

We further studied remodeling dynamically by measuring the serum markers C-telopeptide and osteocalcin. Consistent with the increased Oc.S/BPm (Table 1), serum C-telopeptide levels were markedly elevated in hyperthyroid Tshr–/– mice compared with wild-type hyperthyroid mice (Figure 2C). Concordant with the changes in BFR (Table 1), serum osteocalcin levels were also significantly higher in hyperthyroid Tshr–/– mice (Figure 2D). Interestingly, we did not note increments in remodeling parameters in wild-type mice implanted with 5-mg T4 pellets compared with those receiving 0-mg T4 pellets. This was not unexpected, as after ovariectomy in mice, for example, elevated remodeling occurs very
rapidly, causing profound bone loss within 2–3 weeks, which is followed by a low remodeling state with slower bone loss. This means that we likely missed the hyper-resorption phase in our 21-day experiments. Overall, however, we show that net bone loss is more pronounced in mice deficient in \textit{Tshr}, suggesting an osteoprotective function for TSH signaling, which is lost in hyperthyroidism.

This observation is relevant both clinically and biologically. There is growing evidence for an association between low TSH, low BMD, and increased bone turnover in hyperthyroidism. The risk of vertebral and non-vertebral fractures increases 4.5- and 3.2-fold, respectively, with serum TSH levels of 0.1 IU/l or less (9). Likewise, euthyroid women with serum TSH levels in the lowest tertile of the normal range have a higher incidence of vertebral fractures, independent of thyroid hormone levels (19). Analysis of the National Health and Nutrition Examination Survey (NHANES) data show that the odds ratio for correlations between TSH and bone mass range between 2 and 3.4 (18). Moreover, in the Tromso study, participants with serum TSH levels below 2 SD had significantly lower BMDs (15). In patients taking suppressive doses of T4 for thyroid cancer, serum cathepsin K levels were grossly elevated (16). Importantly, and of clinical relevance, greater bone loss occurs in T4-treated patients with suppressed TSH levels than in those without suppression (12, 13). Our mouse study attempts to reinforce the idea that these clinical observations may not simply be cor-

Table 1
Histomorphometry parameters

<table>
<thead>
<tr>
<th>Tshr\textsuperscript{+/+}</th>
<th>\textbf{TH (0 mg)}</th>
<th>\textbf{TH (5 mg)}</th>
<th>\textbf{P}</th>
<th>Tshr\textsuperscript{−/−}</th>
<th>\textbf{TH (0 mg)}</th>
<th>\textbf{TH (5 mg)}</th>
<th>\textbf{P}</th>
<th>\textbf{P, WT5 vs. KO5}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oc.S/BPm (%)</td>
<td>14.26 ± 1.46</td>
<td>15.33 ± 1.30</td>
<td>0.458</td>
<td>13.10 ± 0.93</td>
<td>20.30 ± 1.42</td>
<td>0.001</td>
<td>0.004</td>
<td></td>
</tr>
<tr>
<td>MS (%)</td>
<td>0.35 ± 0.04</td>
<td>0.36 ± 0.02</td>
<td>0.841</td>
<td>0.29 ± 0.02</td>
<td>0.46 ± 0.03</td>
<td>0.003</td>
<td>0.073</td>
<td></td>
</tr>
<tr>
<td>MAR (\textmu m/d)</td>
<td>1.45 ± 0.13</td>
<td>1.57 ± 0.09</td>
<td>0.544</td>
<td>1.47 ± 0.12</td>
<td>1.56 ± 0.16</td>
<td>0.594</td>
<td>0.991</td>
<td></td>
</tr>
<tr>
<td>BFR (\textmu m\textsuperscript{3}/\mu m\textsuperscript{2}/d)</td>
<td>5.45 ± 0.55</td>
<td>5.55 ± 0.99</td>
<td>0.937</td>
<td>4.57 ± 0.54</td>
<td>7.58 ± 0.75</td>
<td>0.011</td>
<td>0.081</td>
<td></td>
</tr>
<tr>
<td>Os.Th (\textmu m)</td>
<td>1.00 ± 0.82</td>
<td>1.25 ± 0.96</td>
<td>0.703</td>
<td>1.00 ± 0.82</td>
<td>0.80 ± 0.50</td>
<td>0.689</td>
<td>0.438</td>
<td></td>
</tr>
<tr>
<td>sLS/BPm (fraction)</td>
<td>0.44 ± 0.12</td>
<td>0.46 ± 0.11</td>
<td>0.814</td>
<td>0.49 ± 0.15</td>
<td>0.47 ± 0.13</td>
<td>0.847</td>
<td>0.910</td>
<td></td>
</tr>
<tr>
<td>dLS/BPm (fraction)</td>
<td>0.13 ± 0.05</td>
<td>0.10 ± 0.08</td>
<td>0.548</td>
<td>0.06 ± 0.03</td>
<td>0.22 ± 0.11</td>
<td>0.031</td>
<td>0.128</td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{TRAP-positive Oc.S/BPm, MS, MAR, BFR, Os.Th, sLS/BPm, and dLS/BPm in wild-type (Tshr\textsuperscript{+/+}) and Tshr\textsuperscript{−/−} mice implanted with 0-mg (placebo) or 5-mg (WT5 and KO5, respectively) sustained-release T4 pellets (TH) for 21 days are shown. \textit{n} = 6 mice/group.}
relative; instead, low TSH may facilitate the excessive bone loss in human hyperthyroidism. There is therefore a need for caution when TSH supplementation is initiated so as not to unnecessarily lower serum TSH to undetectable levels.

The reverse, which is that a constantly elevated TSH level might be osteoprotective, may or may not be true. We did not find, at least in these short-term studies, significant BMD or BV/TV differences when wild-type and Tshr–/– mice were rendered hypothyroid with 0-mg T4 pellets. Both groups of mice had elevated TSH levels, but with abrogated TSHR signaling in Tshr–/– mice. Nonetheless, in humans, the HUNT 2 study found a positive correlation between TSH and BMD at the distal forearm (17). It also appears from our data using osteoclasts from embryonic stem cells that the agonist TSHR antibody may offer antiresorptive osteoprotection against the bone loss in Graves disease, but this needs further validation in humans (25). Importantly, however, patients harboring the activating TSHR polymorphism D727E have high bone mass (20–22). However, hypothyroid patients can be at a high fracture risk, suggesting that persistently elevated serum TSH levels may, in fact, suppress bone resorption to the ultimate detriment of optimal skeletal remodeling and bone strength (26). Nonetheless, we and others have shown that TSH administered intermittently acts upon the osteoblast to promote bone formation in rodents and humans (5–7).

What is fascinating biologically, however, is that while the two hyperthyroid genotypes have undetectable serum TSH levels and similar T4 levels, Tshr–/– mice lose more bone than wild-type mice. This establishes the TSHR as the only determinant that could account for the bone loss differences between the two genotypes when rendered hyperthyroid. Underscoring this difference, we report the identification of a Tshr splice variant, produced in bone marrow (27), which is regulated positively, rather than negatively, by TSH (Supplemental Figure 1). This molecule, we believe, is capable of exerting a bone-protective effect, which would be lost when the TSHR is deleted. The production of a pituitary hormone–like hormone in bone marrow is not surprising. We and others have shown that anterior pituitary hormones, such as adrenocorticotropic hormone (ACTH) (28), and posterior pituitary hormones, such as oxytocin (29), are produced by bone cells. While their physiologic importance remains unresolved, the possibility of simpler, shorter feedback or feed-forward loops within bone, where GPCRs such as oxytocin (29), are produced by bone cells, is discouraged for pituitary hormones have been identified (30, 31), might be biologically meaningful in the intricate control of skeletal integrity.

Methods

Ten-week-old Tshr–/– mice, originally generated on a mixed C57BL/6 x 129Sv background, were backcrossed for more than 10 generations. The mice were maintained on a 12-hour light/12-hour dark photoperiod. We supplemented Tshr–/– mice with thyroid extract (100 ppm) at weaning (4), but supplementation was suspended at the start of the experiments. Mice were first rendered hypothyroid by addition of 0.5% 2-mercapto-1-methylimidazole (methimazole) to drinking water for 14 days. Thereafter, both groups were implanted with either 0-mg or 5-mg sustained-release thyroid hormone (T4) pellets (Innovative Research of America) for 21 days and were fed normal chow. At 21 days, mice in all groups were sacrificed for histomorphometry and bone marker measurements. Serum T4 and TSH measurements were made using Multiplex assays (Millipore). aBMD was measured using a small animal densitometer (PIXImus, GE-Lunar). Micro-CT (Desktop CT 40, SCANCO) allowed quantification of vBMD, BV/TV, Tb.Th, Tb.N, Tb.Sp, and Conn.D (32). Histomorphometry using calcein (Sigma-Aldrich) and Bisquant 11 (RM Biometrics) provided estimates of MS, mineral apposition rate (MAR), BFR, osteoid thickness (Os.Th), single label fraction (sLS/BPm), and dLS/BPm, while TRAP staining provided Oc.S/BPm (32). Osteocalcin ELISA (Biomedical Technologies) and Rat-Laps ELISA (Nordic Bioscience Diagnostics) were used.

Statistics. Data are expressed as mean ± SEM. Statistical comparisons were carried out using 1-way ANOVA with Bonferroni’s correction and 2-tailed Student’s t test. P values less than 0.05 were considered significant.

Acknowledgments

This work was supported in part by DK080459 (to M. Zaidi), L. Sun, and T.F. Davies), DK069713 and DK052464 (to T.F. Davies), and AG23186 and DK70526 (to M. Zaidi) from the NIH and by the VA Merit Review Program (to T.F. Davies and H.C. Blair). J. Cao is supported by the USDA ARS CRIS Program (5450-51000-046-00D).

Received for publication March 27, 2012, and accepted in revised form July 26, 2012.

Address correspondence to: Mone Zaidi, The Mount Sinai Bone Program, Endocrinology, Box 1050, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, New York 10029, USA. Phone: 212.241.8798; Fax: 212.426.8312; E-mail: mone.zaidi@mssm.edu.